Charles Flexner1,2. 1. Divisions of Clinical Pharmacology and Infectious Diseases, Department of Medicine and Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine. 2. Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: The main reason for the failure of oral preexposure prophylaxis (PrEP) regimens for HIV is poor adherence. Intramuscular cabotegravir was recently approved for PrEP, and a number of other long-acting antiretroviral formulations and products are currently in clinical development. This includes subcutaneous and intravenous injections, implants, and microarray (microneedle) patches, as well as extended duration oral drugs. The success and future uptake of these products will depend on a variety of factors. RECENT FINDINGS: Long-acting delivery of antiretroviral agents for PrEP confers significant advantages over short-acting oral delivery. This is exemplified by the superior efficacy of intramuscular cabotegravir given every eight weeks as compared to daily oral co-formulated tenofovir disoproxil fumarate and emtricitabine. There is also evidence for PrEP efficacy for a broadly neutralizing monoclonal antibody given intravenously every eight weeks. One of the leading candidates for long-acting PrEP, islatravir, was being studied as a monthly oral drug or a nonerodable subcutaneous implant inserted for up to 12 months. However, clinical studies of this agent were put on hold in late 2021 because of unanticipated lymphopenia. SUMMARY: Long-acting antiretroviral products have substantial promise for PrEP and have particular advantages over daily oral drugs based mainly on improved adherence. However, there are barriers to further uptake that include the need for more intensive interaction with systems of healthcare delivery, greater expense and complexity of implementation, and unexpected long-term toxicities.
PURPOSE OF REVIEW: The main reason for the failure of oral preexposure prophylaxis (PrEP) regimens for HIV is poor adherence. Intramuscular cabotegravir was recently approved for PrEP, and a number of other long-acting antiretroviral formulations and products are currently in clinical development. This includes subcutaneous and intravenous injections, implants, and microarray (microneedle) patches, as well as extended duration oral drugs. The success and future uptake of these products will depend on a variety of factors. RECENT FINDINGS: Long-acting delivery of antiretroviral agents for PrEP confers significant advantages over short-acting oral delivery. This is exemplified by the superior efficacy of intramuscular cabotegravir given every eight weeks as compared to daily oral co-formulated tenofovir disoproxil fumarate and emtricitabine. There is also evidence for PrEP efficacy for a broadly neutralizing monoclonal antibody given intravenously every eight weeks. One of the leading candidates for long-acting PrEP, islatravir, was being studied as a monthly oral drug or a nonerodable subcutaneous implant inserted for up to 12 months. However, clinical studies of this agent were put on hold in late 2021 because of unanticipated lymphopenia. SUMMARY: Long-acting antiretroviral products have substantial promise for PrEP and have particular advantages over daily oral drugs based mainly on improved adherence. However, there are barriers to further uptake that include the need for more intensive interaction with systems of healthcare delivery, greater expense and complexity of implementation, and unexpected long-term toxicities.
Authors: Ethel D Weld; Md Sohel Rana; Ronald H Dallas; Andres F Camacho-Gonzalez; Patrick Ryscavage; Aditya H Gaur; Rana Chakraborty; Susan Swindells; Charles Flexner; Allison L Agwu Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Jean A Bernatchez; Rakesh Paul; Egor P Tchesnokov; Marianne Ngure; Greg L Beilhartz; Albert M Berghuis; Rico Lavoie; Lianhai Li; Anick Auger; Roman A Melnyk; Jay A Grobler; Michael D Miller; Daria J Hazuda; Sidney M Hecht; Matthias Götte Journal: J Biol Chem Date: 2014-10-29 Impact factor: 5.157
Authors: Andrea C Wilson; Sivan Vadakkadath Meethal; Richard L Bowen; Craig S Atwood Journal: Expert Opin Investig Drugs Date: 2007-11 Impact factor: 6.206
Authors: Katharine J Bar; Michael C Sneller; Linda J Harrison; J Shawn Justement; Edgar T Overton; Mary E Petrone; D Brenda Salantes; Catherine A Seamon; Benjamin Scheinfeld; Richard W Kwan; Gerald H Learn; Michael A Proschan; Edward F Kreider; Jana Blazkova; Mark Bardsley; Eric W Refsland; Michael Messer; Katherine E Clarridge; Nancy B Tustin; Patrick J Madden; KaSaundra Oden; Sijy J O'Dell; Bernadette Jarocki; Andrea R Shiakolas; Randall L Tressler; Nicole A Doria-Rose; Robert T Bailer; Julie E Ledgerwood; Edmund V Capparelli; Rebecca M Lynch; Barney S Graham; Susan Moir; Richard A Koup; John R Mascola; James A Hoxie; Anthony S Fauci; Pablo Tebas; Tae-Wook Chun Journal: N Engl J Med Date: 2016-11-09 Impact factor: 91.245
Authors: Jianmeng Chen; Charles Flexner; Rosa G Liberman; Paul L Skipper; Nicolette A Louissaint; Steven R Tannenbaum; Craig W Hendrix; Edward J Fuchs Journal: J Acquir Immune Defic Syndr Date: 2012-12-15 Impact factor: 3.731
Authors: Thesla Palanee-Phillips; Marc M Baum; John A Moss; Meredith R Clark; Jeremy Nuttall; Joseph W Romano Journal: Expert Opin Drug Deliv Date: 2022-01-07 Impact factor: 6.648
Authors: Mark A Marzinke; Beatriz Grinsztejn; Jessica M Fogel; Estelle Piwowar-Manning; Maoji Li; Lei Weng; Marybeth McCauley; Vanessa Cummings; Shahnaz Ahmed; Casey D Haines; Lane R Bushman; Christos Petropoulos; Deborah Persaud; Adeola Adeyeye; Ryan Kofron; Alex Rinehart; Marty St Clair; James F Rooney; Daniel Pryluka; Lara Coelho; Aditya Gaur; Keren Middelkoop; Nittaya Phanuphak; Myron S Cohen; Craig W Hendrix; Peter Anderson; Brett Hanscom; Deborah Donnell; Raphael J Landovitz; Susan H Eshleman Journal: J Infect Dis Date: 2021-11-16 Impact factor: 7.759